Fenofibric acid is a hypolipidemic drug that is used as an active ingredient per se or is administered in the form of fenofibrate that releases fenofibric acid after absorption. The metabolism of fenofibric acid is mediated primarily by glucuronidation. However, the other part of fenofibric acid is excreted as reduced fenofibric acid. Enzymes responsible for the formation of reduced fenofibric acid as well
非诺贝特酸是一种降血脂药,本身就用作活性成分,或以非诺贝特的形式给药,在吸收后释放出非诺贝特酸。非诺贝特酸的代谢主要由葡萄糖醛酸化介导。但是,非诺贝特酸的另一部分作为还原的非诺贝特酸排泄。迄今为止,负责还原非诺贝特酸的形成及其亚细胞定位的酶仍是未知的。我们发现非诺贝特酸还原的主要部位是人的肝细胞溶质,而肝微粒体将非诺贝特酸还原到较低的程度,并且对这种药物表现出较低的亲和力(K m > 1000μM)。在测试的9种羰基还原酶(CRE)中,CBR1表现出最大的非诺贝特酸还原(CLint = 85.975μl/ mg蛋白质/分钟)。根据体内数据,CBR1主要是还原的非诺贝酸的(-)-对映异构体,类似于肝细胞溶质。AKR1C1,AKR1C2,AKR1C3和AKR1B1也被确定为非诺贝特酸的还原酶,但预计仅在非诺贝特酸代谢中起次要作用。